Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Clinical Question·Updated Jul 4, 2026·v1

first-line rate versus rhythm control in newly diagnosed atrial fibrillation [Grok-4.3]

No randomized trials or meta-analyses among the provided references directly compare first-line rate control versus first-line rhythm control in patients with newly diagnosed atrial fibrillation for the outcomes of mortality, stroke, hospitalization, or quality of life. Magnitude of effects is not quantified in the retrieved

Moderate Evidence15 references·1,167 words·5 min read·v1
No randomized trials or meta-analyses among the provided references directly compare first-line rate control versus first-line rhythm control in patients with newly diagnosed atrial fibrillation for the outcomes of mortality, stroke, hospitalization, or quality of life. Magnitude of effects is not quantified in the retrieved evidence.

Board Review — High Yield

  • •No direct rate-versus-rhythm comparisons appear in the supplied abstracts
  • •Antiarrhythmic drugs increase AF recurrence versus catheter ablation in paroxysmal (RR 1.76) and persistent AF (RR 1.62) [3].
  • •Catheter ablation lowers atrial fibrillation recurrence versus antiarrhythmic drugs in treatment-naive paroxysmal, AAD-exposed persistent, and previously ablated paroxysmal atrial fibrillation (RR range 1.62-2.12) [3].
  • •Evidence strongest in persistent AF plus heart failure where extensive ablation cut composite events to 17.0% at 36 months [5]
  • •Catheter ablation lowers AF recurrence versus antiarrhythmic drugs in paroxysmal (RR 1.76) and persistent subgroups (RR 2.12) [3]

Deep Dive — Evidence Details

References

  1. [1]

    Farah MH, Hegazi M, Firwana M et al.. “A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40658500 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Rodriguez-Riascos JF, Navale D, Somappa A et al.. “Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 41930400 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  3. [3]

    Idema DL, Kusters MPT, Huis In 't Veld LF et al.. “Antiarrhythmic drugs vs catheter ablation as rhythm control for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.” Heart rhythm (2026). PMID: 41881373 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  4. [4]

    Vedage NA, Friedman SF, Chang Y et al.. “Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence-Enabled Electrocardiogram Models: A VITAL-AF Trial Analysis.” Journal of the American College of Cardiology (2026). PMID: 41983618 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  5. [5]

    Li K, Wang X, Qin M et al.. “Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 41914182 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  6. [6]

    Tao J, Liu K, Cheng T et al.. “Clinical efficacy and mechanistic study of fulvning granules in symptomatic atrial fibrillation: a randomized controlled trial with untargeted metabolomics analysis.” Frontiers in pharmacology (2026). PMID: 41815911 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  7. [7]

    Kawaji T, Aizawa T, Shizuta S et al.. “Head-to-head comparison of two atrial fibrillation driver mapping systems for additional ablation in persistent atrial fibrillation: The CONTROL-AF trial.” International journal of cardiology (2026). PMID: 41702445 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  8. [8]

    Petersen J, Stock S, Brettschneider C et al.. “Interdisciplinary and Cross-Sectoral Perioperative Care Model in Cardiac Surgery: ERAS Implementation in the Setting of Minimally Invasive Heart Valve Surgery (INCREASE)-Results of a Randomized Controlled Trial.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 41619774 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  9. [9]

    Humayun Z, Majeed MW, Joshi DK et al.. “Pulsed-field ablation versus thermal ablation for atrial fibrillation: an updated systematic review and meta -analysis of randomized controlled trials and observational studies with time-to-event analysis.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026). PMID: 41910891 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Ahmed O, Behr ER, White S et al.. “Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial.” Journal of the American Heart Association (2026). PMID: 42216292 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Jensen M, Zapf A, Buchholz A et al.. “Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE): protocol for an international investigator-initiated, prospective, randomised, open, blinded endpoint assessment (PROBE) interventional multi-centre trial.” European stroke journal (2026). PMID: 42153760 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Okutucu S, Gorenek B. “Current Recommendations on Atrial Fibrillation: A Comparison of the Recent European and Canadian Guidelines.” Cardiology (2021). PMID: 34547752 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line
  13. [13]

    Dorian P, Alings M, Coutu B et al.. “Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.” Journal of cardiovascular electrophysiology (2026). PMID: 41668514 ↗

    L2TRIAL_NONRANDOMCited in: Current Evidence and Standard
  14. [14]

    Golian M, Ramirez FD, Cleland M et al.. “MAX-SHOCK: A Pragmatic Randomized Controlled Trial Comparing Biphasic Defibrillators Used in Routine Cardioversion of Atrial Fibrillation.” CJC open (2026). PMID: 42327430 ↗

    L1RCTCited in: Current Evidence and Standard
  15. [15]

    van Steijn NJ, Blommestijn IS, Blok S et al.. “Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.” Journal of the American College of Cardiology (2026). PMID: 41569211 ↗

    L1RCTCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…